8 results about "Platelet inhibition" patented technology

The objective is to provide a method that suppresses the formation of pseudopods of platelets during the preparation of PRP, thereby preventing the formation of aggregates. [Solution] The method for producing platelet-rich plasma (PRP) according to the present invention is characterized by adding a local anesthetic to the blood when producing PRP.

This invention relates to the field of biomedicine, specifically to the application of banana fruit extract in the preparation of anticoagulant or antithrombotic drugs. The banana fruit extract provided by this invention contains flavonoids, polyphenols, polysaccharides, hydroxyanthraquinones, triterpenoids, and other components. Flavonoids and polyphenols have been widely proven to have anti-inflammatory and antioxidant effects, which can synergistically enhance the anticoagulant effect. The high potassium content of banana fruit can indirectly improve vascular function by regulating sodium-potassium balance. The banana fruit extract provided by this invention can inhibit platelet production or promote platelet metabolism, prolong clotting time, and inhibit platelet aggregation. Its natural plant components interfere with platelet aggregation by inhibiting the production of thromboxane A2, achieving anticoagulant and antithrombotic effects. The mechanism of action of banana fruit extract differs from traditional anticoagulants such as heparin, reducing the risk of bleeding. Its natural component characteristics provide a direction for the development of novel plant-derived anticoagulant drugs.

This invention belongs to the field of traditional Chinese medicine (TCM) technology, specifically relating to a TCM composition with detoxifying and uterus-warming effects and its application in the preparation of external products. The medicinal component of this external TCM product is composed of fenugreek, amethyst, rose, pomegranate seed, centella asiatica, long pepper, five-finger peach, lycopodium, litchi seed, and achyranthes bidentata. Animal experiments show that this product can significantly reduce the number of writhing movements in animals with cold-induced blood stasis type dysmenorrhea, lower COX-2 and PGE2 levels in the uterus, and improve peritoneal inflammation, demonstrating good detoxifying, blood stasis-removing, menstruation-regulating, and pain-relieving effects. Regarding blood rheology, it exhibits the effects of inhibiting platelet aggregation, dilating blood vessels, reducing blood viscosity, and balancing TXA2 and PGI2 levels, reflecting its effects of warming the kidneys and uterus, and strengthening the body's foundation. In summary, the TCM composition of this invention and its prepared external product can warm the kidneys and uterus, promote diuresis and eliminate turbidity, providing a novel TCM external application solution for the clinical treatment of cold-induced blood stasis type dysmenorrhea.

The present application provides a Bifidobacterium breve. The strain has high yield of acetoin and has milk clotting function. The present application provides a fermenting agent comprising the Bifidobacterium breve. The preparation method of the fermenting agent is also provided. The present application also provides a fermented ovine colostrum, which contains a plurality of functional polypeptides. The present application also provides a preparation method of the fermented ovine colostrum. The method can simultaneously ensure high retention rate of nutrients in the ovine colostrum. The present application also provides a polypeptide. The polypeptide can inhibit angiotensin converting enzyme activity, improve vascular endothelial function or inhibit platelet aggregation, and has cardiovascular protection ability. The present application also provides a polypeptide composition. The present application also provides application of the Bifidobacterium breve, the polypeptide and / or the fermented ovine colostrum in the field of food or medicine for helping to enhance immunity.

The application belongs to the field of thrombus-related circulatory disorder disease treatment, and provides application of a Rev-erb alpha agonist in preparation of an anti-platelet aggregation and thrombus-related circulatory disorder medicine. The application finds a new pharmacological effect of the Rev-erb alpha agonist, which can significantly inhibit platelet activation and aggregation, block arterial thrombosis in the whole circulatory system, and increase the level of ischemic area cortical blood supply within 0.5 to 1 hours after stroke. The blood supply increasing approach is recanalization of the infarction area circulatory system, rather than compensation by collateral supply arteries, finally significantly improving motor dysfunction caused by cerebral infarction; and the application provides a new idea and a new drug selection for clinical treatment of coronary heart disease, limb arterial thrombosis, visceral thrombosis, ischemic stroke, disseminated intravascular coagulation, peripheral thrombosis and the like.

The application discloses an enhanced anti-coagulation and anti-bacterial hemodialysis hollow fiber membrane and a preparation method thereof, and belongs to the technical field of medical membrane materials. The acid activation-polydopamine coating-sulfonated grafting modification of halloysite nanotubes is carried out in the application, so that the surface sulfonic acid group density of the halloysite nanotubes reaches 0.8-2.1 mmol / g, and the Zeta potential is less than or equal to-30 mV. The modified halloysite is dispersed in a polar aprotic solvent in advance, is incorporated into a polymer matrix after ultrasonic treatment, is filtered through a sintering filter element with a diameter of less than or equal to 5 mu m, is defoamed, is spun by using a dry spraying-wet spinning method, and is prepared into a finished product through coagulation, rinsing and drying. The application constructs a heparin-like negative charge layer, so that the activated partial thromboplastin time (APTT) is greater than or equal to 55 s, platelet adhesion and protein adsorption are significantly inhibited, and the application has a broad-spectrum antibacterial performance. The rigid halloysite induces the formation of through channels, so that the pain point that a high-flux membrane is easy to damage red blood cells is solved, the process is stable, and the application is suitable for industrial production.

The present invention relates to: a pharmaceutical composition for preventing or treating thrombotic diseases, the pharmaceutical composition comprising a compound of chemical formula 1 or an acceptable salt thereof; and a health functional food composition or cosmetic composition which is for improving blood circulation and comprises same Specifically, in the present invention, the compound of chemical formula 1 was found to simultaneously inhibit NOX1 and NOX2 and thus be highly effective in inhibiting platelet aggregation and thrombus formation.

The application belongs to the technical field of biological medicine, and particularly relates to a Buthus martensii Karsch (Buthus martensii Karsch) oligopeptide and application thereof in preparation of anti-platelet and anti-thrombus drugs or compositions. Buthus martensii The application discloses an anti-platelet oligopeptide discovered by combining an active-oriented separation with computer virtual screening based on a Karsch transcriptome database. The oligopeptide can not only inhibit platelet aggregation, but also effectively inhibit platelet adhesion and expansion. In a thrombus model experiment in vivo, the Buthus martensii Karsch oligopeptide discovered by the application can well inhibit FeCl3-induced carotid artery thrombosis of a mouse. Meanwhile, it is found that the Buthus martensii Karsch oligopeptide does not have obvious bleeding tendency. In conclusion, the Buthus martensii Karsch oligopeptide can be used as an anti-platelet aggregation and anti-thrombus drug to play a certain positive role in the prevention and treatment of thrombotic diseases.